Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
FENTANYL (FENTANYL CITRATE)
STERIMAX INC
N01AH01
FENTANYL
250MCG
SOLUTION
FENTANYL (FENTANYL CITRATE) 250MCG
INTRAMUSCULAR
15G/50G
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0123302002; AHFS:
APPROVED
2020-02-10
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Ⓝ FENTANYL INJECTION BP Fentanyl 50 mcg/mL as fentanyl citrate Narcotic Analgesic Adjunct to Anesthesia SteriMax Inc. Date of Preparation: February 6, 2020 2770 Portland Drive Oakville, ON Canada L6H 6R4 Submission Control No: 227834 _FENTANYL INJECTION BP _ _Page 2 of 46 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ...............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................13 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION ..............................................................................16 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY .............................................................21 STORAGE AND STABILITY .............................................................................................. 24 SPECIAL HANDLING INSTRUCTIONS ........................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25 PART II: SCIENTIFIC INFORMATION ................................................................................26 PHARMACEUTICAL INFORMATION ..........................................................................26 DETAILED PHARMACOLOGY ................................ Belgenin tamamını okuyun